Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does LENALIDOMIDE Cause Malignant neoplasm progression? 1,150 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 1,150 reports of Malignant neoplasm progression have been filed in association with LENALIDOMIDE (LENALIDOMIDE). This represents 0.3% of all adverse event reports for LENALIDOMIDE.

1,150
Reports of Malignant neoplasm progression with LENALIDOMIDE
0.3%
of all LENALIDOMIDE reports
295
Deaths
202
Hospitalizations

How Dangerous Is Malignant neoplasm progression From LENALIDOMIDE?

Of the 1,150 reports, 295 (25.7%) resulted in death, 202 (17.6%) required hospitalization, and 44 (3.8%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for LENALIDOMIDE. However, 1,150 reports have been filed with the FAERS database.

What Other Side Effects Does LENALIDOMIDE Cause?

Diarrhoea (27,576) Fatigue (22,956) Death (19,213) Off label use (17,017) Rash (15,794) Pneumonia (14,807) Plasma cell myeloma (14,191) Neuropathy peripheral (10,215) White blood cell count decreased (9,996) Constipation (9,635)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which LENALIDOMIDE Alternatives Have Lower Malignant neoplasm progression Risk?

LENALIDOMIDE vs LENIOLISIB LENALIDOMIDE vs LENOGRASTIM LENALIDOMIDE vs LENVATINIB LENALIDOMIDE vs LEPONEX LENALIDOMIDE vs LERCANIDIPINE

Related Pages

LENALIDOMIDE Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression LENALIDOMIDE Demographics